Martin Gouldstone
Chief Executive Officer
Martin brings 30 years corporate finance and business development experience in the CRO, healthcare and pharmaceutical sectors to his role as CEO at Oncimmune. Most recently, Martin was a Global SVP Business Development at Owkin, where he managed all of the commercial teams in the USA and Europe and led new strategic research partnerships. Over the last few years, Martin was Chief Business Officer at Sensyne Health where he helped to drive growth with particular focus on expanding reach in the US market and Pharmaceutical sector; Global SVP at Syneos One and Head of Capital Solutions for Syneos Healthcare where he developed and led Capital Solutions service; Chief Business Officer at BenevolentAI where he was responsible for all commercial activities. He was previously a Partner at Results Healthcare, where he co-led the healthcare practice;Head of Lifesciences in the UK for BDO, the Lead for the M&A process in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant, Pharmacopeia, Sareum. He has extensive experience buying and selling multi-billion dollar deals across Europe and the US, architecting end to end portfolio out-sourcing deals, and negotiating multi-year research partnerships. Currently, Martin is a Non-Executive Board Director for hVIVO Plc and sits on the Board of Trustees of Orthopaedic Research UK. He holds a BSc in Genetics and has completed a range of post graduate management courses.
Martin Hudson
Chief Financial Officer
Martin graduated from the University of Liverpool with a Bachelor of Science degree in Mathematical Sciences with German, and has since worked for more than 20 years in commercially and operationally focused finance roles. He brings international experience in fast-moving project-driven high technology sectors.
Martin became a member of the Chartered Institute of Management Accountants while working at Ford of Europe in the UK and Germany. He moved to an EMEA FP&A role at Gilbarco Veeder Root, a subsidiary of Danaher, and then to McLaren Automotive where he was responsible for the financial control of vehicle development programmes and operational set up at a time of significant investment. Between 2012 and 2021, Martin held Finance Director roles at McLaren Electronic Systems, McLaren Applied Technologies and Williams Advanced Engineering, contributing to the growth of all three companies in their core areas of automotive and motorsport, as well as in adjacent markets including healthcare and financial services. Before joining Oncimmune in 2023, Martin was Director of Project Finance at a Slovakian battery company incorporated in Norway.
Petra Budde
Chief Scientific Officer
Petra is the Chief Scientific Officer at Oncimmune Germany GmbH, a position she has held since 2023. Petra led the Medical Research department of Protagen AG from 2012 and on the acquisition of Protagen AG by Oncimmune in 2019 Petra assumed the role of Director of Medical Research. Prior to joining Oncimmune, she held senior management positions at Proteome Sciences (Frankfurt, Germany) and Digilab BioVisioN (Hanover, Germany), where she led autoimmune disease, diabetes, and oncology biomarker development programmes. In her previous roles, Petra worked for biomarker discovery companies specializing in proteomics and gained extensive experience in omics-type biomarker programmes, collaborating with pharma, biotech, and academic partners to address the need for biomarkers throughout all phases of clinical drug development. Throughout her career, she has specialised in B cell-mediated immunity, antigen presentation, autoimmunity, and allergy. She received her PhD (Dr. rer. nat.) from the University of Bielefeld (Germany) and was a Postdoctoral Fellow at the Laboratory of Molecular Biology (LMB) in Cambridge, UK.
Hans-Dieter Zucht
Chief Technical Officer
Hans-Dieter is an expert in biomarker and bioinformatics, boasting over 25 years at the forefront of the field. As the Chief Technical Officer (CTO) at Oncimmune, he leads groundbreaking initiatives in autoimmunity, cancer research and diagnostics technology. He began his career after earning his Diploma in Biochemistry in Hannover, Germany, in 1991, followed by a PhD under Prof. Forssmann in 1994 at the Lower Saxony Institute of Peptide Research, specializing in bioactive peptides. In 1996, he joined BioVision, significantly advancing the nascent field of Peptidomics by integrating mass spectrometry with pioneering data science techniques. Since 2008, Hans-Dieter led the Proteomics Operations at Proteome Sciences in Frankfurt. He did his Habilitation in 2003, and is a visiting Professor at Paris-Lodron University in Salzburg, Austria. His prolific academic output includes over 50 influential publications, numerous book chapters, and several patents. He was member of numerous EU grants and reviewer for the European Union. His research focuses on biomarkers and data mining of highly dimensional data using cutting-edge multiplex technologies.
Since joining Protagen Diagnostics in Germany in 2013—later part of Oncimmune—he has transformed the technology to a world-class standard by integrating state-of-the-art Luminex technologies, advanced data science methodologies, and rigorous quality control systems.
Mike Fisher
Vice President, Head of Business Development
Mike has a PhD in medicinal chemistry and 28 years’ experience of life sciences business development, commercialisation, project management and government relations. He has worked in both the public and private sectors, focusing on biotech business development for the past 16 years. Mike joined Oncimmune in 2017 and drove the adoption strategy for EarlyCDT Lung in the UK/Europe and Oncimmune’s move into precision medicine services. Following the sale of the early cancer detection business in 2023, Mike rebuilt Oncimmune’s Commercial Team and moved the BD office to Boston MA, USA where he is now based. Mike joined Oncimmune from Abcodia, where he was Director of Strategic Alliances, focusing on biomarker validation for early detection of cancer and other diseases. Before this he was Business Development Director for Bio Nano Consulting, a spin-out from University College London and Imperial College. Between 2005 and 2008, Mike was the UK government’s Life Sciences Industry Advisor for North America, based in Cambridge MA, where he liaised between US corporates and the Department of Health, NICE and MHRA. Prior to moving to the US Mike worked in life science economic development in the public sector and provided internationalisation consultancy to life science companies. Before this, Mike performed his post-doctoral research at DSTL Porton Down, developing detection systems for toxins and pathogens, where he became the Project Manager for their Blue Sky research programmes in biological detection.
In addition to his role with Oncimmune, Mike is Vice President and Board member of the British American Business Council for New England, founder of the Boston Biotech Brits and a member of the Advisory Board of BioPartner UK.